Table 2.

Base case analysis results

Condition	Cost per patient	Effectiveness	ICERa	NMBb
Utility: QALYS
Baseline (REP only)	588.95	0.47	0	46911.05
REP+EF only	637.53	0.48	Dominatedc	47822.00
REP+EF, add IF if needed	627.40	0.54	593.42d	53351.18
REP+EF/IF	625.95	0.47	Dominatedc	45987.68

^aICER: incremental cost-effectiveness ratio

^bNMB: net monetary benefit. Willingness-to-pay threshold $100,000/QALY [45]

^cDominated: more expensive and less effective than comparators [46]

^dSince “REP+EF/IF” is dominated, “REP+EF, add IF if needed” is compared to REP only